Association Between Liver Fibrosis, Plasma Volume Status, and Cardiovascular Mortality: The Hiroshima Study on Glucose Metabolism and Cardiovascular Diseases
European Journal of Heart Failure · 2025
DOI: 10.1002/ejhf.3677 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift European Journal of Heart Failure, 2025. Verfasst von Nobuo Sasaki und 4 weiteren Autor:innen. Beteiligte Einrichtung: Health Management and Promotion Center, Hiroshima Atomic Bomb Casualty Council, Hiroshima, Japan. Hauptthemen laut MEDLINE: Liver Cirrhosis, Cardiovascular Diseases, Plasma Volume, Blood Glucose. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 33 Literaturangaben.
Abstract (Originalsprache)
Aims
Increasing evidence shows an interrelationship between liver injury and cardiovascular disease. This study aimed to investigate the interrelationship between subclinical congestion, liver fibrosis, and cardiovascular disease mortality. Methods and results This retrospective cohort study, using data from the Hiroshima Study on Glucose Metabolism and Cardiovascular Diseases, included 8689 participants (mean age 69.7 years, 49.1% women) who were recruited during health checkups. Liver fibrosis and systemic congestion were assessed by the fibrosis-4 (FIB-4) index and plasma volume status (PVS), respectively. PVS was modestly but significantly associated with the FIB-4 index at baseline. During a median follow-up of 9.3 years, 387 (4.5%) cardiovascular deaths occurred. The incidence rates of cardiovascular mortality were 3.95, 5.15, and 14.5 per 1000 person-years in the low (<1.3), indeterminate (1.3–2.67), and high FIB-4 index (>2.67) groups, respectively. In the multivariable Cox proportional hazard regression analysis, compared with the low FIB-4 index group, the high FIB-4 index group showed significantly increased hazard ratios (HRs) for mortality due to cardiovascular (HR 2.34; 95% confidence interval [CI] 1.78–3.06), cardiac (HR 2.43; 95% CI 1.75–3.39), and cerebrovascular (HR 2.18; 95% CI 1.37–3.48) diseases, even after adjusting for PVS. Moreover, the incidence of heart failure-related mortality, but not ischaemic heart disease-related mortality, was increased in the indeterminate FIB-4 index group.
Conclusions
Systemic congestion may partially contribute to the progression of liver fibrosis, and advanced liver fibrosis increases cardiovascular mortality rates, independent of congestion, and heart failure-related mortality was more prominent than ischaemic heart disease-related mortality.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Health Management and Promotion Center, Hiroshima Atomic Bomb Casualty Council, Hiroshima, Japan.
- Department of Regenerative Medicine, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan.
- Department of General Medicine, Hiroshima University Graduate School of Biomedical and Health Sciences, Hiroshima, Japan.
- Department of Cardiovascular Medicine, Hiroshima University Graduate School of Biomedical and Health Sciences, Hiroshima, Japan.
ORCID-Profile: Nobuo Sasaki
Zitieren
APA
Sasaki, N., Ueno, Y., Ozono, R., Nakano, Y., & Higashi, Y. (2025). Association Between Liver Fibrosis, Plasma Volume Status, and Cardiovascular Mortality: The Hiroshima Study on Glucose Metabolism and Cardiovascular Diseases. European Journal of Heart Failure. https://doi.org/10.1002/ejhf.3677
Vancouver
Sasaki N, Ueno Y, Ozono R, Nakano Y, Higashi Y. Association Between Liver Fibrosis, Plasma Volume Status, and Cardiovascular Mortality: The Hiroshima Study on Glucose Metabolism and Cardiovascular Diseases. European Journal of Heart Failure. 2025. doi:10.1002/ejhf.3677
BibTeX
@article{Sasaki2025,
author = {Sasaki, Nobuo and Ueno, Yoshitaka and Ozono, Ryoji and Nakano, Yukiko and Higashi, Yukihito},
title = {Association Between Liver Fibrosis, Plasma Volume Status, and Cardiovascular Mortality: The Hiroshima Study on Glucose Metabolism and Cardiovascular Diseases},
journal = {European Journal of Heart Failure},
year = {2025},
doi = {10.1002/ejhf.3677}
}
EUVIMED